Introduction
============

Chondrosarcoma is a malignant tumour originating from cartilage tissue and is the second most common malignant bone tumour after osteosarcomas worldwide ([@b1-ol-0-0-10329],[@b2-ol-0-0-10329]). Chondrosarcoma primarily occurs in individuals \>50 years of age and, in the majority of cases, affects the limbs and pelvis ([@b3-ol-0-0-10329]). Pathological types can be divided into conventional intramedullary chondrosarcoma, clear cell chondrosarcoma, mesenchymal chondrosarcoma, juxtacortical chondrosarcoma and myxoid chondrosarcoma ([@b4-ol-0-0-10329],[@b5-ol-0-0-10329]). Chondrosarcoma has a poor response to traditional chemotherapy and radiotherapy, and surgical resection is currently the only successful treatment available ([@b6-ol-0-0-10329]--[@b8-ol-0-0-10329]).

In recent years, second primary cancer types have become more prominent, and the incidence and risk of second primary cancer is increasing in countries such as the USA and the Netherlands ([@b9-ol-0-0-10329],[@b10-ol-0-0-10329]). This increase may be due to a significant improvement in the survival times of those adults with cancer or the use of commonly used cancer treatments such as radiotherapy or chemotherapy ([@b11-ol-0-0-10329]--[@b13-ol-0-0-10329]). In the present study, second primary chondrosarcoma (pCS) is defined as a tumour that is different in location or histology from the initial pCS and is not derived from the metastasis or recurrence of the initial pCS. Chondrosarcoma rarely presents as a second primary tumour ([@b10-ol-0-0-10329]).

To the best of our knowledge, no studies have evaluated the prognosis or treatment differences between the initial pCS and the second pCS thus far. The purpose of the present study was to analyse the difference in prognosis between the initial and second pCS, and the difference in treatment outcomes on the basis of a population-level study of chondrosarcoma.

Materials and methods
=====================

### Data source and patients

The Surveillance Epidemiology and End Results (SEER) database (<https://seer.cancer.gov/>) of the National Cancer Institute (Bethesda, MD, USA) was used as the data source in the present study. In total, 3,055 patients with initial and second pCS were identified using the International Classification of Diseases for Oncology (ICD-O-3) (<http://codes.iarc.fr/>) histology codes 9220/3,9221/3,9231/3,9240/3,9242/3 and 9243/3. The patients had been diagnosed between January 1, 2004, and December 31, 2015. SEER\*Stat software (version 8.3.5; National Cancer Institute) was used to access the SEER 18 Regs Custom Data (with an additional treatment field) Nov 2017 Sub (1973--2015 varying) database using the client-server mode of SEER\*Stat. Patients with unknown survival time, unknown American Joint Committee on Cancer (AJCC) stage or unknown Tumour-Node-Metastasis (TNM) stage ([@b14-ol-0-0-10329]), as well as those diagnosed at autopsy, \<18 years of age or having a non-initial visit to hospital and non-osteoarticular chondrosarcoma were excluded. The National Cancer Institute\'s SEER database covers \~30% of the population in the USA, and collects information such as demographics, tumour histology, tumour stage at diagnosis, treatment information and survival time ([@b15-ol-0-0-10329]). Finally, 1,655 eligible patients were identified.

The second pCS may be synchronous or metachronous. The definitions of the second pCS met the following criteria: i) Synchronous cancer is a second pCS diagnosed simultaneously or within 6 months of diagnosis of the initial pCS ([@b9-ol-0-0-10329]); ii) metachronous cancer is a diagnosis of second pCS ≥6 months following the diagnosis of an initial pCS; iii) the primary site differs between the initial pCS and the second pCS; iv) histology is different if the primary site is the same as the primary site of the initial primary cancer.

### Study variables

Overall survival (OS) and cancer-specific survival (CSS) were the primary outcomes in the present study. The patients in the present study were categorized into two groups: Initial pCS and second pCS. The following variables were extracted for analysis: Year of diagnosis, age at diagnosis, sex, ethnicity, marital status, area of geographical state, urban-rural residence, laterality, primary site, tumour grade, histological type, AJCC stage, extent of disease (for T and M stages), regional nodes positive (for N stage) and treatment methods (surgery, radiotherapy or chemotherapy).

### Statistical analysis

The baseline data of demographics and clinicopathological characteristics of the initial and second pCS were compared using χ^2^ tests. Kaplan-Meier curves and log-rank tests were used for OS and CSS. Univariable analysis was performed using the log-rank test to determine the factors associated with all-cause mortality and cancer-specific mortality. Furthermore, univariable and multivariable Cox regression analyses were used to determine the factors associated with all-cause mortality and cancer-specific mortality. All statistical analyses were performed using SPSS statistics software (version 20; IBM Corp., Armonk, NY, USA). P≤0.05 was considered to indicate a statistically significant result.

Results
=======

### Demographic and clinical characteristics of the initial and second pCS

In total, 1,655 eligible patients with chondrosarcoma who were diagnosed between January 1, 2004, and December 31, 2015, were included in the cohort of the present study, with data obtained from the SEER database between January 1, 2004, and December 31, 2015. Among them, 1,455 (87.9%) patients had initial pCS and 200 (12.1%) patients had second pCS. The clinical characteristics and the χ^2^ test for comparison of the initial and second pCS are presented in [Table I](#tI-ol-0-0-10329){ref-type="table"}. The data presented in [Table I](#tI-ol-0-0-10329){ref-type="table"} indicates that the incidence of chondrosarcoma increases with the year of diagnosis. χ^2^ test revealed significant differences between the initial and second pCS in certain variables, including year of diagnosis (P=0.048), age at diagnosis (P\<0.001), tumour AJCC stage (P=0.024) and M-stage (P=0.044). Patients with second pCS were more frequently diagnosed at 61--80 years of age (52.5 vs. 43.1%; P\<0.001) compared with patients with initial pCS. Furthermore, the majority of patients with initial and second pCS chose to receive surgical treatment (92.0 and 91.0% respectively), and markedly less patients chose to receive radiotherapy (14.8 and 15.0%, respectively) or chemotherapy (8.0 vs. 5.5%, respectively).

### Univariate survival analyses of factors associated with all-cause mortality and cancer-specific mortality

Univariate survival analyses of patients with initial and second pCS according to various clinicopathological variables ([Table II](#tII-ol-0-0-10329){ref-type="table"}). Among the 1,655 initial and second pCS patients, 390 (23.6%) were categorized as cases of all-cause mortality and 228 (13.8%) succumbed to chondrosarcoma. Univariate analyses revealed that year of diagnosis, age at diagnosis, sex, tumour grade, histological type, AJCC stage, TNM stage, surgery, radiotherapy and chemotherapy were associated with all-cause mortality and chondrosarcoma-associated mortality (all P\<0.05). In addition, patients with second pCS had a higher rate of all-cause mortality compared with patients with initial pCS (P\<0.001), but there was no significant difference between initial and second pCS in terms of chondrosarcoma-associated mortality (P=0.734).

### Survival

The median survival time among the entire cohort was 41.00 months, with patients with initial pCS experiencing a longer median survival time (42.00 months), and patients with second pCS experiencing a shorter median survival time (34.50 months). [Fig. 1A](#f1-ol-0-0-10329){ref-type="fig"} presents the OS and CSS of the initial and second pCS. The OS rate of patients with initial pCS was significantly higher compared with that of the patients with second pCS (log-rank test, P\<0.001), but the CSS rate of the patients with initial pCS was not significantly different from that of the patients with second pCS (log-rank test, P=0.428). In addition, it was also revealed that among the pathological types of chondrosarcoma, dedifferentiated chondrsarcoma exhibited the worst OS and CSS rates ([Fig. 1B](#f1-ol-0-0-10329){ref-type="fig"}). Patients were stratified by primary sites and laterality, and in doing so, it was revealed that the OS rate of the patients with initial pCS was also higher compared with that of the patients with second pCS. However, there was no significant difference between the initial and second pCS in terms of chondrosarcoma-associated mortality ([Fig. 2](#f2-ol-0-0-10329){ref-type="fig"}).

### Risk factors for all-cause mortality and cancer-specific mortality

Univariate and multivariate Cox regression were used to analyse the factors associated with all-cause mortality and cancer-specific mortality ([Table III](#tIII-ol-0-0-10329){ref-type="table"}). Age at diagnosis, sex, histological type, AJCC stage, T stage, surgery and radiotherapy were associated with all-cause mortality and chondrosarcoma-cause mortality (all P\<0.05) in univariate and multivariate Cox regression. In the multivariate Cox regression analysis among patients with initial and second pCS, age 41--60 years \[vs. age 18--40 years; HR, 1.80; 95% confidence interval (CI), 1.22--2.65; P=0.003\], age 61--80 years (vs. age 18--40 years; HR, 2.91; 95% CI, 1.97--4.30; P\<0.001), age \>80 years (vs. age 18--40 years; HR, 4.04; 95% CI, 2.49--6.57; P\<0.001), male (vs. female; HR, 1.50; 95% CI, 1.21--1.85; P\<0.001), moderately differentiated (vs. well-differentiated; HR, 1.41; 95% CI, 1.03--1.93; P=0.033), undifferentiated (vs. well-differentiated; HR, 2.00; 95% CI, 1.09--3.68; P=0.026), mesenchymal chondrosarcoma (vs. chondrosarcoma, NOS; HR, 2.11; 95% CI, 1.03--4.33; P=0.042), dedifferentiated chondrosarcoma (vs. chondrosarcoma, NOS; HR, 3.00; 95% CI, 2.20--4.08; P\<0.001), AJCC stage IV (vs. AJCC stage I; HR, 5.67; 95% CI, 3.64--8.82; P\<0.001), T2 stage (vs. T1 stage; HR, 1.81; 95% CI, 1.46--2.25; P\<0.001), surgery (vs. no surgery; HR, 0.39; 95% CI, 0.29--0.52; P\<0.001), radiotherapy (vs. no radiotherapy; HR, 1.31; 95% CI, 1.03--1.67; P=0.030) and second pCS (vs. initial pCS; HR, 1.72; 95% CI, 1.31--2.26; P\<0.001) were associated with a significant increase in all-cause mortality. However, initial and second pCS were still not associated with improved chondrosarcoma-associated survival on multivariable survival analysis (P=0.294).

### Benefits of different treatment for initial and second pCS

To analyse the benefit of different treatments for all-cause mortality, patients with initial and second pCS were stratified by primary site and laterality, and multivariate analysis was used. For patients with appendicular or axial chondrosarcoma, those with initial and second pCS who underwent surgery had lower all-cause mortality (all P\<0.05; [Fig. 3A](#f3-ol-0-0-10329){ref-type="fig"}) compared with patients who did not receive surgery ([Fig. 3A](#f3-ol-0-0-10329){ref-type="fig"}). Similarly, for left-sided or right-sided chondrosarcoma patients, those with initial and second pCS who underwent surgery had lower all-cause mortality rate (all P\<0.05) compared with patients without surgery. However, the use of radiotherapy or chemotherapy did not reduce the all-cause mortality rate ([Fig. 3B and C](#f3-ol-0-0-10329){ref-type="fig"}).

Discussion
==========

The incidence of chondrosarcoma accounts for \~20% of all primary bone sarcomas ([@b16-ol-0-0-10329]). Above the age of 40 years, the incidence rate of chondrosarcoma gradually increases, and the incidence rate in men is higher than that in women. Rozeman *et al* ([@b17-ol-0-0-10329]) reported that common types of chondrosarcoma accounted for 85% of cases, dedifferentiation for 10%, interstitial type for 2% and clear cell type for 1%. Giuffrida *et al* ([@b18-ol-0-0-10329]) analysed 2,890 cases of chondrosarcoma between 1973 and 2003, and revealed that the highest 5-year survival rate was that of clear cell type chondrosarcoma (100%), followed by common chondrosarcoma (70%), and the lowest was that of dedifferentiated chondrosarcoma (0%). The results from the present study also revealed that dedifferentiated chondrosarcoma has the worst prognosis.

Second pCS is a rare occurrence, and, to the best of our knowledge, there are currently no studies that have assessed the prognosis and treatment differences between the initial pCS and the second pCS. Therefore, the present study is the first to report differences in prognosis and treatment between initial pCS and the second pCS.

The present study revealed that the proportion of the four age stages (18--40, 41--60, 61--80 and \>80 years) of the patients with initial pCS were 26.3, 43.1, 26.5 and 4.2%, respectively, while the proportion of the patients with second pCS in the four age stages was 5.0,32.0,52.5 and 10.5%, respectively. It was demonstrated that patients with second pCS were at an older age when diagnosed compared with patients with initial pCS. The difference may be due to a significant improvement in survival for patients with cancer.

As one of the multiple primary malignancies (MPMs), the second primary cancer has received greater attention. MPMs are rarely encountered in different organs and tissues in the same patient, and the incidence of MPMs ranges from 0.7--11.0%, as determined through the statistical analysis of several national cancer registries ([@b10-ol-0-0-10329],[@b19-ol-0-0-10329],[@b20-ol-0-0-10329]). The most common subsequent types of cancer are squamous cell skin cancer, colorectal cancer and breast cancer ([@b13-ol-0-0-10329]). Patients with MPMs exhibit a worse 5-year OS rate compared with patients with a single malignancy ([@b21-ol-0-0-10329]). This may be associated with genetic, environmental and immunological factors, as well as the application of radiotherapy or chemotherapy ([@b22-ol-0-0-10329],[@b23-ol-0-0-10329]).

The risk of developing a subsequent cancer in patients with MPMs was 1.4 to 3.0 times higher compared to the general population ([@b13-ol-0-0-10329]). There are a number of studies that have focused on second primary tumours. By investigating 2,462 patients with hepatocellular carcinoma who underwent liver transplantation, Heo *et al* ([@b24-ol-0-0-10329]) revealed that patients with hepatocellular carcinoma who had received a liver transplantation had a longer life expectancy and higher risk of second primary cancer compared with the general population (standardized incidence ratios, 2.79; 95% CI, 2.27--3.38). Chen *et al* ([@b25-ol-0-0-10329]) demonstrated that the prognosis of patients with second primary colorectal cancer was worse than that of patients with initial primary colorectal cancer, and the therapeutic benefit on colorectal cancer prognosis was generally similar for the patients with initial and second primary colorectal cancer. The present study revealed similar results; it was identified that patients with second pCS had a worse prognosis compared with patients with initial pCS, and the treatment benefits were similar for patients with initial and second pCS. Surgery can significantly reduce all-cause mortality, while the use of radiotherapy or chemotherapy does not reduce all-cause mortality.

Furthermore, in terms of demographic and clinical characteristics, χ^2^ tests revealed a significant difference in the age at diagnosis for patients with initial pCS and those patients with second pCS; patients with second pCS were diagnosed at an older age compared with patients with initial pCS.

The present study does have certain limitations. First, the research is based on the SEER database, a retrospective dataset that therefore has inherent limitations. Secondly, the patients' physical condition was unclear; patients with excessive comorbidities may pursue more conservative treatment. In addition, the number of patients included in the present study was small, so further prospective studies are necessary.

The results of the present study revealed that patients with second pCS were more frequently diagnosed at an older age and had a worse prognosis compared with patients with initial pCS. For patients with initial and second pCS, surgery was the main treatment method.
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![Kaplan-Meier analysis demonstrating the overall survival (left) and cancer-specific survival (right) of (A) patients with initial pCS and second pCS (log-rank tests, P\<0.001) and (B) patients with different histological types. pCS, primary chondrosarcoma; NOS, not otherwise specified.](ol-18-01-0207-g00){#f1-ol-0-0-10329}

###### 

Overall survival (left) and cancer-specific survival (right) of patients with initial pCS vs. second pCS for (A and B) appendicular chondrosarcoma, (C and D) axial chondrosarcoma, (E and F) left-sided chondrosarcoma and (G and H) right-sided chondrosarcoma. pCS, primary chondrosarcoma.
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###### 

Forest plot presenting the interaction between patients with initial and second primary chondrosarcoma undergoing (A) surgical treatment, (B) radiotherapy and (C) chemotherapy. CI, confidence interval.
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###### 

Characteristics of patients stratified by initial and second pCS.

  Characteristics                     All patients   Initial pCS    Second pCS   P-value
  ----------------------------------- -------------- -------------- ------------ ---------
  Total, n (%)                        1,655          1,455 (87.9)   200 (12.1)   
  Median survival, months             41.00          42.00          34.50        
  Year of diagnosis, n (%)                                                       0.048
    2004--2006                        343 (20.7)     299 (20.5)     44 (22.0)    
    2007--2009                        399 (24.1)     363 (24.9)     36 (18.0)    
    2010--2012                        427 (25.8)     362 (24.9)     65 (32.5)    
    2013--2015                        486 (29.4)     431 (29.6)     55 (27.5)    
  Age at diagnosis in years, n (%)                                               \<0.001
    18--40                            392 (23.7)     382 (26.3)     10 (5.0)     
    41--60                            691 (41.8)     627 (43.1)     64 (32.0)    
    61--80                            490 (29.6)     385 (26.5)     105 (52.5)   
    \>80                              82 (5.0)       61 (4.2)       21 (10.5)    
  Sex, n (%)                                                                     0.724
    Female                            742 (44.8)     650 (44.7)     92 (46.0)    
    Male                              913 (55.2)     805 (55.3)     108 (54.0)   
  Ethnicity, n (%)                                                               0.882
    Caucasian                         1,444 (87.3)   1,269 (87.2)   175 (87.5)   
    African-American                  111 (6.7)      99 (6.8)       12 (6.0)     
    Other                             100 (6.0)      87 (6.0)       13 (6.5)     
  Marital status, n (%)                                                          0.265
    Married                           957 (57.8)     831 (57.1)     126 (63.0)   
    Single                            622 (37.6)     555 (38.1)     67 (33.5)    
    Unknown                           76 (4.6)       69 (4.7)       7 (3.5)      
  State, n (%)                                                                   0.751
    West                              875 (52.9)     763 (52.4)     112 (56.0)   
    Northeast                         300 (18.1)     267 (18.4)     33 (16.5)    
    South                             334 (20.2)     294 (20.2)     40 (20.0)    
    Midwest                           146 (8.8)      131 (9.0)      15 (7.5)     
  Urban-rural residence, n (%)                                                   0.650
    Metropolitan                      1,472 (88.9)   1,296 (89.1)   176 (88.0)   
    Non-metropolitan                  183 (11.1)     159 (10.9)     24 (12.0)    
  Laterality, n (%)                                                              0.907
    Left                              633 (38.2)     554 (38.1)     79 (39.5)    
    Right                             676 (40.8)     597 (41.0)     79 (39.5)    
    Other                             346 (20.9)     304 (20.9)     42 (21.0)    
  Primary site, n (%)                                                            0.542
    Appendicular                      803 (48.5)     710 (48.8)     93 (46.5)    
    Axial                             852 (51.5)     745 (51.2)     107 (53.5)   
  Grade, n (%)                                                                   0.505
    Well-differentiated               575 (34.7)     513 (35.3)     62 (31.0)    
    Moderately differentiated         684 (41.3)     603 (41.5)     81 (40.5)    
    Poorly differentiated             230 (13.9)     198 (13.6)     32 (16.0)    
    Undifferentiated                  141 (8.5)      119 (8.2)      22 (11.0)    
    Unknown                           25 (1.5)       22 (1.5)       3 (1.5)      
  Histological type, n (%)                                                       0.633
    Chondrosarcoma, NOS               1,353 (81.8)   1,191 (81.9)   162 (81.0)   
    Juxtacortical chondrosarcoma      21 (1.3)       19 (1.3)       2 (1.0)      
    Myxoid chondrosarcoma             102 (6.2)      93 (6.4)       9 (4.5)      
    Mesenchymal chondrosarcoma        18 (1.1)       16 (1.1)       2 (1.0)      
    Clear cell chondrosarcoma         11 (0.7)       10 (0.7)       1 (0.5)      
    Dedifferentiated chondrosarcoma   150 (9.1)      126 (8.7)      24 (12.0)    
  AJCC stage, n (%)                                                              0.024
    I                                 1,213 (73.3)   1,072 (73.7)   141 (70.5)   
    II                                307 (18.5)     257 (17.7)     50 (25.0)    
    III                               18 (1.1)       16 (1.1)       2 (1.0)      
    IV                                117 (7.1)      110 (7.6)      7 (3.5)      
  T-stage, n (%)                                                                 0.593
    T1                                1,020 (61.6)   903 (62.1)     117 (58.5)   
    T2                                608 (36.7)     528 (36.3)     80 (40.0)    
    T3                                27 (1.6)       24 (1.6)       3 (1.5)      
  N-stage, n (%)                                                                 0.359
    N0                                1,636 (98.9)   1,437 (98.8)   199 (99.5)   
    N1                                19 (1.1)       18 (1.2)       1 (0.5)      
  M-stage, n (%)                                                                 0.044
    M0                                1,552 (93.8)   1,358 (93.3)   194 (97.0)   
    M1                                103 (6.2)      97 (6.7)       6 (3.0)      
  Surgery, n (%)                                                                 0.617
    No                                134 (8.1)      116 (8.0)      18 (9.0)     
    Yes                               1,521 (91.9)   1,339 (92.0)   182 (91.0)   
  Radiotherapy, n (%)                                                            0.934
    No                                1,410 (85.2)   1,240 (85.2)   170 (85.0)   
    Yes                               245 (14.8)     215 (14.8)     30 (15.0)    
  Chemotherapy, n (%)                                                            0.207
    No                                1,527 (92.3)   1,338 (92.0)   189 (94.5)   
    Yes                               128 (7.7)      117 (8.0)      11 (5.5)     

Percentages may not total 100 due to rounding. AJCC, American Joint Committee on Cancer; pCS, primary chondrosarcoma; NOS, not otherwise specified.

###### 

Univariate survival analyses of the 1,655 patients with chondrosarcoma according to various clinicopathological variables.

                                      All-cause                   Chondrosarcoma-associated                               
  ----------------------------------- ------------ -------------- --------------------------- ------------ -------------- ---------
  Total patients in study             390 (23.6)   1,265 (76.4)                               228 (13.8)   1,427 (86.2)   
  Year of diagnosis                                               \<0.001                                                 \<0.001
    2004--2006                        120 (30.8)   223 (17.6)                                 68 (29.8)    275 (19.3)     
    2007--2009                        109 (27.9)   290 (22.9)                                 62 (27.2)    337 (23.6)     
    2010--2012                        109 (27.9)   318 (25.1)                                 69 (30.3)    358 (25.1)     
    2013--2015                        52 (13.3)    434 (34.3)                                 29 (12.7)    457 (32.0)     
  Age at diagnosis, years                                         \<0.001                                                 \<0.001
    18--40                            38 (9.7)     354 (28.0)                                 27 (11.8)    365 (25.6)     
    41--60                            142 (36.4)   549 (43.4)                                 92 (40.4)    599 (42.0)     
    61--80                            167 (42.8)   323 (25.5)                                 93 (40.8)    397 (27.8)     
    \>80                              43 (11.0)    39 (3.1)                                   16 (7.0)     66 (4.6)       
  Sex                                                             \<0.001                                                 0.041
    Female                            144 (36.9)   598 (47.3)                                 88 (38.6)    654 (45.8)     
    Male                              246 (63.1)   667 (52.7)                                 140 (61.4)   773 (54.2)     
  Ethnicity                                                       0.390                                                   0.862
    Caucasian                         339 (86.9)   1,105 (87.4)                               201 (88.2)   1,243 (87.1)   
    African-American                  31 (7.9)     80 (6.3)                                   15 (6.6)     96 (6.7)       
    Other                             20 (5.1)     80 (6.3)                                   12 (5.3)     88 (6.2)       
  Marital status                                                  0.352                                                   0.491
    Married                           220 (56.4)   737 (58.3)                                 135 (59.2)   822 (57.6)     
    Single                            156 (40.0)   466 (36.8)                                 86 (37.7)    536 (37.6)     
    Unknown                           14 (3.6)     62 (4.9)                                   7 (3.1)      69 (4.8)       
  State                                                           0.469                                                   0.309
    West                              209 (53.6)   666 (52.6)                                 129 (56.6)   746 (52.3)     
    Northeast                         65 (16.7)    235 (18.6)                                 35 (15.4)    265 (18.6)     
    South                             75 (19.2)    259 (20.5)                                 40 (17.5)    294 (20.6)     
    Midwest                           41 (10.5)    105 (8.3)                                  24 (10.5)    122 (8.5)      
  Urban-rural residence                                           0.836                                                   0.684
    Metropolitan                      348 (89.2)   1,124 (88.9)                               201 (88.2)   1,271 (89.1)   
    Non-metropolitan                  42 (10.8)    141 (11.1)                                 27 (11.8)    156 (10.9)     
  Laterality                                                      0.941                                                   0.224
    Left                              152 (39.0)   481 (38.0)                                 94 (41.2)    539 (37.8)     
    Right                             158 (40.5)   518 (40.9)                                 96 (42.1)    580 (40.6)     
    Other                             80 (20.5)    266 (21.0)                                 38 (16.7)    308 (21.6)     
  Primary site                                                    0.887                                                   0.532
    Appendicular                      188 (48.2)   615 (48.6)                                 115 (50.4)   688 (48.2)     
    Axial                             202 (51.8)   650 (51.4)                                 113 (49.6)   739 (51.8)     
  Grade                                                           \<0.001                                                 \<0.001
    Well-differentiated               61 (15.6)    514 (40.6)                                 26 (11.4)    549 (38.5)     
    Moderately differentiated         133 (34.1)   551 (43.6)                                 76 (33.3)    608 (42.6)     
    Poorly differentiated             87 (22.3)    143 (11.3)                                 56 (24.6)    174 (12.2)     
    Undifferentiated                  89 (22.8)    52 (4.1)                                   60 (26.3)    81 (5.7)       
    Unknown                           20 (5.1)     5 (0.4)                                    10 (4.4)     15 (1.1)       
  Histological type                                               \<0.001                                                 \<0.001
    Chondrosarcoma, NOS               242 (62.1)   1,111 (87.7)                               137 (60.1)   1,216 (85.2)   
    Juxtacortical chondrosarcoma      2 (0.5)      19 (1.5)                                   2 (0.9)      19 (1.3)       
    Myxoid chondrosarcoma             29 (7.4)     73 (5.8)                                   20 (8.8)     82 (5.7)       
    Mesenchymal chondrosarcoma        10 (2.6)     8 (0.6)                                    7 (3.1)      11 (0.8)       
    Clear cell chondrosarcoma         3 (0.8)      8 (0.6)                                    0 (0.0)      11 (0.8)       
    Dedifferentiated chondrosarcoma   104 (26.7)   46 (3.6)                                   62 (27.2)    88 (6.2)       
  AJCC stage                                                      \<0.001                                                 \<0.001
    I                                 164 (42.1)   1,049 (82.9)                               75 (32.9)    1,138 (79.7)   
    II                                126 (32.3)   181 (14.3)                                 78 (34.2)    229 (16.0)     
    III                               6 (1.5)      12 (0.9)                                   3 (1.3)      15 (1.1)       
    IV                                94 (24.1)    23 (1.8)                                   72 (31.6)    45 (3.2)       
  T-stage                                                         \<0.001                                                 \<0.001
    T1                                151 (38.7)   869 (68.7)                                 80 (35.1)    940 (65.9)     
    T2                                226 (57.9)   382 (30.2)                                 141 (61.8)   467 (32.7)     
    T3                                13 (3.3)     14 (1.1)                                   7 (3.1)      20 (1.4)       
  N-stage                                                         \<0.001                                                 \<0.001
    N0                                378 (96.9)   1,258 (99.4)                               220 (96.5)   1,416 (99.2)   
    N1                                12 (3.1)     7 (0.6)                                    8 (3.5)      11 (0.8)       
  M-stage                                                         \<0.001                                                 \<0.001
    M0                                304 (77.9)   1,248 (98.7)                               161 (70.6)   1,391 (97.5)   
    M1                                86 (22.1)    17 (1.3)                                   67 (29.4)    36 (2.5)       
  Surgery                                                         \<0.001                                                 \<0.001
    No                                74 (19.0)    60 (4.7)                                   44 (19.3)    90 (6.3)       
    Yes                               316 (81.0)   1,205 (95.3)                               184 (80.7)   1,337 (93.7)   
  Radiotherapy                                                    \<0.001                                                 \<0.001
    No                                293 (75.1)   1,117 (88.3)                               166 (72.8)   1,224 (87.2)   
    Yes                               97 (24.9)    148 (11.7)                                 62 (27.2)    183 (12.8)     
  Chemotherapy                                                    \<0.001                                                 \<0.001
    No                                308 (79.0)   1,219 (96.4)                               170 (74.6)   1,357 (95.1)   
    Yes                               82 (21.0)    46 (3.6)                                   58 (25.4)    70 (4.9)       
  Group                                                           \<0.001                                                 0.734
    Initial pCS                       316 (81.0)   1,139 (90.0)                               202 (88.6)   1,253 (87.8)   
    Second pCS                        74 (19.0)    126 (10.0)                                 26 (11.4)    174 (12.2)     

Includes those patients that succumbed to causes other than chondrosarcoma and those that were still alive. Percentages may not total 100 due to rounding. AJCC, American Joint Committee on Cancer; pCS, primary chondrosarcoma; NOS, not otherwise specified; T, tumor; N, node; M, metastasis.

###### 

Risk factors for survival: Outcome is all-cause mortality and cancer-specific mortality.

                                      All-cause mortality    Cancer-specific mortality                                                                                       
  ----------------------------------- ---------------------- --------------------------- ------------------- --------- ---------------------- --------- -------------------- ---------
  Age at diagnosis, years                                                                                                                                                    
    18--40                            Reference                                          Reference                     Reference                        Reference            
    41--60                            2.34 (1.63--3.34)      \<0.001                     1.80 (1.22--2.65)   0.003     2.16 (1.41--3.32)      \<0.001   1.86 (1.14--3.02)    0.013
    61--80                            4.47 (3.14--6.35)      \<0.001                     2.91 (1.97--4.30)   \<0.001   3.77 (2.45--5.78)      \<0.001   2.79 (1.71--4.56)    \<0.001
    \>80                              8.52 (5.50--13.21)     \<0.001                     4.04 (2.49--6.57)   \<0.001   5.60 (3.01--10.39)     \<0.001   3.50 (1.81--6.80)    \<0.001
  Sex                                                                                                                                                                        
    Female                            Reference                                          Reference                     Reference                        Reference            
    Male                              1.46 (1.19--1.80)      \<0.001                     1.50 (1.21--1.85)   \<0.001   1.40 (1.07--1.83)      0.014     1.40 (1.06--1.85)    0.017
  Grade                                                                                                                                                                      
    Well-differentiated               Reference                                          Reference                     Reference                        Reference            
    Moderately differentiated         1.95 (1.44--2.64)      \<0.001                     1.41 (1.03--1.93)   0.033     2.65 (1.69--4.13)      \<0.001   NA                   0.128
    Poorly differentiated             4.51 (3.25--6.26)      \<0.001                     1.51 (0.84--2.71)   0.169     7.14 (4.49--11.38)     \<0.001   NA                   0.532
    Undifferentiated                  10.62 (7.65--14.73)    \<0.001                     2.00 (1.09--3.68)   0.026     17.51 (11.04--27.78)   \<0.001   NA                   0.297
    Unknown                           15.53 (9.34--25.82)    \<0.001                     0.95 (0.49--1.85)   0.878     25.74 (12.37--53.56)   \<0.001   NA                   0.583
  Histological type                                                                                                                                                          
    Chondrosarcoma, NOS               Reference                                          Reference                     Reference                        Reference            
    Juxtacortical chondrosarcoma      0.51 (0.13--2.04)      0.340                       0.71 (0.18--2.90)   0.636     0.86 (0.21--3.47)      0.830     1.10 (0.27--4.50)    0.900
    Myxoid chondrosarcoma             1.61 (1.09--2.36)      0.016                       1.19 (0.80--1.76)   0.400     2.02 (1.26--3.23)      0.003     1.72 (1.06--2.77)    0.027
    Mesenchymal chondrosarcoma        3.61 (1.92--6.80)      \<0.001                     2.11 (1.03--4.33)   0.042     4.74 (2.22--10.14)     \<0.001   2.37 (0.97--5.80)    0.058
    Clear cell chondrosarcoma         1.45 (0.46--4.53)      0.523                       1.72 (0.54--5.45)   0.360     NA                     NA        NA                   NA
    Dedifferentiated chondrosarcoma   7.84 (6.21--9.92)      \<0.001                     3.00 (2.20--4.08)   \<0.001   9.68 (7.14--13.13)     \<0.001   3.43 (2.41--4.87)    \<0.001
  AJCC stage                                                                                                                                                                 
    I                                 Reference                                          Reference                     Reference                        Reference            
    II                                3.90 (3.09--4.92)      \<0.001                     1.53 (0.89--2.61)   0.124     5.49 (4.00--7.54)      \<0.001   2.91 (2.03--4.16)    \<0.001
    III                               2.46 (1.09--5.55)      0.031                       1.11 (0.35--3.53)   0.863     2.86 (0.90--9.08)      0.074     1.98 (0.42--9.34)    0.391
    IV                                14.12 (10.88--18.32)   \<0.001                     5.67 (3.64--8.82)   \<0.001   24.47 (17.57--34.09)   \<0.001   4.26 (1.69--10.79)   0.002
  T-stage                                                                                                                                                                    
    T1                                Reference                                          Reference                     Reference                        Reference            
    T2                                3.13 (2.54--3.85)      \<0.001                     1.81 (1.46--2.25)   \<0.001   3.82 (2.91--5.03)      \<0.001   1.94 (1.44--2.60)    \<0.001
    T3                                4.03 (2.29--7.11)      \<0.001                     2.20 (0.98--4.90)   0.055     4.40 (2.03--9.53)      \<0.001   1.43 (0.50--4.10)    0.502
  N-stage                                                                                                                                                                    
    N0                                Reference                                          Reference                     Reference                        Reference            
    N1                                3.95 (2.22--7.03)      \<0.001                     NA                  0.167     5.19 (2.56--10.52)     \<0.001   NA                   0.260
  M-stage                                                                                                                                                                    
    M0                                Reference                                          Reference                     Reference                        Reference            
    M1                                10.69 (8.33--13.71)    \<0.001                     NA                  0.085     15.86 (11.79--21.34)   \<0.001   3.13 (1.23--7.99)    0.017
  Surgery                                                                                                                                                                    
    No                                Reference                                          Reference                     Reference                        Reference            
    Yes                               0.25 (0.19--0.32)      \<0.001                     0.39 (0.29--0.52)   \<0.001   0.22 (0.16--0.30)      \<0.001   0.54 (0.36--0.81)    0.003
  Radiotherapy                                                                                                                                                               
    No                                Reference                                          Reference                     Reference                        Reference            
    Yes                               2.16 (1.71--2.71)      \<0.001                     1.31 (1.03--1.67)   0.030     2.53 (1.89--3.39)      \<0.001   1.47 (1.08--2.01)    0.015
  Chemotherapy                                                                                                                                                               
    No                                Reference                                          Reference                     Reference                        Reference            
    Yes                               4.44 (3.47--5.67)      \<0.001                     NA                  0.943     6.19 (4.58--8.35)      \<0.001   NA                   0.827
  Group                                                                                                                                                                      
    Initial pCS                       Reference                                          Reference                     Reference                        Reference            
    Second pCS                        1.87 (1.45--2.41)      \<0.001                     1.72 (1.31--2.26)   \<0.001   1.18 (0.78--1.77)      0.429     NA                   0.294

AJCC, American Joint Committee on Cancer; CI, confidence interval; NA, not applicable; pCS, primary chondrosarcoma; NOS, not otherwise specified.

[^1]: Contributed equally
